According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

Parkinson’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide. In the United ...

Combining levodopa with a DDC inhibitor (DDCI), such as carbidopa or benserazide, greatly reduces the incidence of nausea and vomiting, increases the levodopa half-life from approximately 60 to 90 ...

2008). On 24 April 2020, the United States Food and Drug Administration approved of opicapone as an adjunctive treatment to carbidopa/levodopa therapy in patients with PD experiencing OFF episodes.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...